As of July 10, 2024, AMPYRA® (dalfampridine), INBRIJA® (levodopa inhalation powder) and ARCUS® technology have been acquired by Merz Therapeutics and will continue to be available to customers through Merz Therapeutics. Click here for more information.

As of August 21, 2024 Acorda Therapeutics Inc. exited Chapter 11 bankruptcy and all remaining assets are now the property of Acorda Therapeutics Liquidation Trust. For additional information concerning the Acorda Therapeutics Inc. Chapter 11 Plan of Reorganization or Acorda Therapeutics Liquidation Trust please visit https://cases.ra.kroll.com/Acorda/.